Cover Image

Exposure‐response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040)

Abstract This analysis was conducted to inform dose selection of a combination of nivolumab plus ipilimumab for the treatment of sorafenib‐experienced patients with hepatocellular carcinoma (HCC). CheckMate 040 is an open‐label, multicohort, phase I/II trial in adults with advanced HCC that evaluate...

Full description

Saved in:

Bibliographic Details
Main Authors:	Bruno Sangro (Author), Thomas Yau (Author), Anthony B. El‐Khoueiry (Author), Masatoshi Kudo (Author), Yun Shen (Author), Marina Tschaika (Author), Amit Roy (Author), Yan Feng (Author), Ling Gao (Author), Urvi Aras (Author)
Format:	Book
Published:	Wiley, 2023-08-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Check and Checkmate
by: Miller, Walter M., 1923-1996; Beecham, Tom, 1926-2000 [Illustrator]

Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
by: Zhou S, et al.
Published: (2019)

Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and Meta-Analysis
by: Yi Yang, et al.
Published: (2020)

Pediatric model‐based dose optimization using a pooled exposure-response safety analysis for nivolumab and nivolumab plus ipilimumab combination in melanoma
by: Shengnan Du, et al.
Published: (2024)

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer
by: Xiaomin Wan, et al.
Published: (2021)

Urticaria multiforme following nivolumab-ipilimumab therapy
by: Sonal Muzumdar, et al.
Published: (2020)

Ipilimumab and nivolumab for recurrent neuroendocrine cervical carcinoma
by: Mary Towner, et al.
Published: (2022)

Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies
by: Jason Zhang, et al.
Published: (2019)

Checkmate
by: Le Fanu, Joseph Sheridan, 1814-1873

A case of nearly complete response in hepatocellular carcinoma with disseminated lung metastasis by combination therapy of nivolumab and ipilimumab after treatment failure of atezolizumab plus bevacizumab
by: Hyung Jun Kim, et al.
Published: (2023)

Population Pharmacokinetics of Ipilimumab in Combination With Nivolumab in Patients With Advanced Solid Tumors
by: Kinjal Sanghavi, et al.
Published: (2020)

Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma
by: Zhuo-miao Ye, et al.
Published: (2022)

Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non-small-cell Lung Cancer
by: Xuezhi Hao, et al.
Published: (2021)

Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma
by: Matthew D. Tucker, et al.
Published: (2021)

A case of ruptured Baker's cyst induced by nivolumab and ipilimumab
by: Marie Kubo, et al.
Published: (2023)

Antitumor Activity and Treatment-Related Toxicity Associated With Nivolumab Plus Ipilimumab in Advanced Malignancies: A Systematic Review and Meta-Analysis
by: Hang Xu, et al.
Published: (2019)

Nivolumab plus ipilimumab with chemotherapy in metastatic NSCLC: minireview and a case study of a patient negative for PD-L1
by: Alessandro Morabito
Published: (2024)

Checkmates for Three Pieces
by: Fishburne, William Brett

Nivolumab and ipilimumab population pharmacokinetics in support of pediatric dose recommendations-Going beyond the body‐size effect
by: Zheyi Hu, et al.
Published: (2024)

Photosensitive Dermatitis Induced by Nivolumab/Ipilimumab Combination Therapy in a Patient with Malignant Melanoma
by: Yuri Sakaguchi, et al.
Published: (2020)

Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma
by: Pramod Savarapu, et al.
Published: (2021)

Stage IV renal cell carcinoma achieves pathologic complete response after two ipilimumab plus nivolumab courses despite severe immune-related adverse events: a case report
by: Ryo Takada, et al.
Published: (2024)

Sequential therapy with INCAGN01949 followed by ipilimumab and nivolumab in two patients with advanced ovarian carcinoma
by: Andrey Moiseyenko, et al.
Published: (2020)

Checkpoint inhibitor immunotherapy induced inflammatory arthritis secondary to Nivolumab and Ipilimumab: a pediatric first
by: John A. Storwick, et al.
Published: (2024)

Nivolumab and Ipilimumab Acting as Tormentors of Advanced Tumors by Unleashing Immune Cells and Associated Collateral Damage
by: Bushra Khan, et al.
Published: (2024)

Hyponatremia and Fever in a Patient on Ipilimumab and Nivolumab (Immune Checkpoint Inhibitors): A Case Report
by: Sumit S. Patel MD, et al.
Published: (2021)

Lichen striatus as an immune-related adverse event following ipilimumab/nivolumab and COVID-19 infection in an adult
by: Courtney M. Kenyon, BS, et al.
Published: (2024)

Successful treatment of HIV-negative Kaposi sarcoma with ipilimumab and nivolumab and concurrent management of baseline psoriasis and bullous pemphigoid
by: Mika M. Tabata, BS, et al.
Published: (2020)

The Automobile Girls at Washington; Or, Checkmating the Plots of Foreign Spies
by: Crane, Laura Dent

Comparisons of therapeutic efficacy and safety of ipilimumab plus GM-CSF versus ipilimumab alone in patients with cancer: a meta-analysis of outcomes
by: Chen P, et al.
Published: (2018)

Successful treatment of nivolumab and ipilimumab triggered type 1 diabetes by using sodium-glucose transporter 2 inhibitor: a case report and systematic review
by: Makoto Fujiwara, et al.
Published: (2023)

CLINICAL AND ECONOMIC EVALUATION OF ATEZOLIZUMAB + VEMURAFENIB + COBIMETINIB COMBINATION AND NIVOLUMAB + IPILIMUMAB COMBINATION: ADMINISTRATION IN METASTATIC MELANOMA TREATMENT WITH BRAF-CONFIRMED MUTATION IN ADULT PATIENTS
by: I. S. Krysanov, et al.
Published: (2022)

Panhypopituitarism induced by ipilimumab
by: Miyu Shiratori, et al.
Published: (2020)

Ipilimumab: Melanoma and beyond
by: Vishal Patel, et al.
Published: (2011)

Evaluating nivolumab plus gemcitabine-cisplatin's cost-effectiveness for aUC in China
by: Kehui Meng, et al.
Published: (2024)

Prevalence of Stafne's Cyst - A retrospective analysis of 18,040 Orthopantomographs in Western India
by: Sugandha Arya, et al.
Published: (2019)

Use of ipilimumab in the treatment of melanoma
by: Acharya UH, et al.
Published: (2013)

Ipilimumab-Induced Neutropenia in Melanoma
by: Makiko Ban-Hoefen MD, et al.
Published: (2016)

Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma
by: Hsin-Yu Kuo, et al.
Published: (2022)

A Case of Erythema Multiforme Major Developed after Sequential Use of Two Immune Checkpoint Inhibitors, Nivolumab and Ipilimumab, for Advanced Melanoma: Possible Implication of Synergistic and/or Complementary Immunomodulatory Effects
by: Akira Utsunomiya, et al.
Published: (2018)